Abbott touts data from rotor-ablation AF trial

Abbott (NYSE:ABT) today announced results from 3 clinical studies of focal impulse rotor modulation guided rotor ablation for treating atrial fibrillation using the company’s RhythmView technology, touting high rates of freedom from AF.

Results from the investigator-sponsored studies, which explored the benefits of FIRM-guided rotor ablation combined with traditional AF care, were presented at Cardiostim-EHRA Europace 2016, the company said.

“The latest data presented at Cardiostim adds to a growing body of clinical evidence in support of the Firm-guided approach in combination with conventional ablation, with the goals of optimizing treatment planning for atrial fibrillation and improving long-term results for our patients. I look forward to additional analyses that further investigate this important therapy option,” Stefan Spitzer of Dresden, Germany’s Praxisklinik Herz und Gefäße said in a prepared statement.

The company said that FIRM-guided therapy allows physicians to identify and locate rotors, which are specific sources that sustain serious hearth rhythm disorders including AF, and tailor treatment to each patient.

Data from a 58-patient study reported an 80.8% rate of freedom from atrial fibrillation at 12-months post-treatment with FIRM-guided ablation for redo cases of persistent atrial fibrillation, with 83% of patients having long-standing persistent atrial fibrillation.

A 138-patient registry study reported 78% and 72% in sinus rhythm following treatment with FIRM-guided ablation at 6 and 12 months, and data from a 47-patient trial examining the relationship between stable rotors and obstructive sleep apnea showed 78.6% of patients in sinus rhythm after FIRM-guided ablation despite obstructive sleep apnea.

“The data presented at Cardiostim last week affirm the positive results achieved with the FIRM-guided approach. These results are consistent with the findings of the Confirm and Oasis studies, which show a clear incremental benefit associated with the use of rotor mapping when performed in conjunction with the traditional ablation procedure,” electrophysiology biz GM Michael Pederson said in a press release.

The post Abbott touts data from rotor-ablation AF trial appeared first on MassDevice.

from MassDevice http://ift.tt/28PaNM0